# EDGAR Filing Document

**Accession Number:** 0000010795
**File Stem:** 0001628280-26-023185
**Filing Date:** 2026-4
**Character Count:** 34256
**Document Hash:** 6f48da10324bbb4af2006b8ecc50d40e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-023185.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001628280-26-023185

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260402

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BECTON DICKINSON & CO
- **CENTRAL INDEX KEY:** 0000010795
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 220760120
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04802
- **FILM NUMBER:** 26833834

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BECTON DR
- **CITY:** FRANKLIN LAKES
- **STATE:** NJ
- **ZIP:** 07417-1880
- **BUSINESS PHONE:** 2018476800

**MAIL ADDRESS:**
- **STREET 1:** ONE BECTON DR
- **CITY:** FRANKLIN LAKE
- **STATE:** NJ
- **ZIP:** 07417

?xml version='1.0' encoding='ASCII'? bdx-20260402

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT PURSUANT TO**

**SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) April 2, 2026**

---

| |
|:---|
| **BECTON, DICKINSON AND COMPANY** |
| (Exact Name of Registrant as Specified in Its Charter) |
| **New Jersey** |
| (State or Other Jurisdiction of Incorporation) |

---

---

| | | | |
|:---|:---|:---|:---|
| **001-4802** | **001-4802** | **001-4802** | **22-0760120** |
| (Commission File Number) | (Commission File Number) | (Commission File Number) | (IRS Employer Identification No.) |
| **1 Becton Drive,** | **Franklin Lakes,** | **New Jersey** | **07417-1880** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

---

| | |
|:---|:---|
| **(201)**  | **847-6800** |
| (Registrant's Telephone Number, Including Area Code) | (Registrant's Telephone Number, Including Area Code) |
| **N/A** | **N/A** |
| (Former Name or Former Address, if Changed Since Last Report) | (Former Name or Former Address, if Changed Since Last Report) |

---

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of Each Class</u>** | **<u>Trading Symbol</u>** | **Name of each exchange on** <br>**<u>which registered</u>** |
| Common stock, par value $1.00 | BDX | New York Stock Exchange |
| 1.900% Notes due December 15, 2026 | BDX26 | New York Stock Exchange |
| 1.208% Notes due June 4, 2026 | BDX/26A | New York Stock Exchange |
| 1.213% Notes due February 12, 2036 | BDX/36 | New York Stock Exchange |
| 3.519% Notes due February 8, 2031 | BDX31 | New York Stock Exchange |
| 3.828% Notes due June 7, 2032 | BDX32A | New York Stock Exchange |

---

------

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging growth company  | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

------

**ITEM 2.02&nbsp;&nbsp;&nbsp;&nbsp;RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

As previously disclosed, on February 9, 2026, Becton, Dickinson and Company ("BD") completed the spin-off of its Biosciences and Diagnostic Solutions business and combination of the business with Waters Corporation. In order to assist investors, BD has furnished as Exhibit 99.1 recast historical financial information, which reflects the presentation of BD's former Biosciences and Diagnostics Solutions business as discontinued operations to provide a historical baseline of BD's standalone operating results from continuing operations and excluding specified items.

The information furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles ("non-GAAP measures"). Details regarding these non-GAAP measures and adjustments can be found in the schedules furnished as Exhibit 99.1.

The information contained in this Current Report on Form 8-K and Exhibit 99.1 hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

------

**ITEM 9.01&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit <u>[99.1](ex991042026.htm)</u>&nbsp;&nbsp;&nbsp;&nbsp; BD Unaudited Recast Financial Information, which is furnished pursuant to Item 2.02.

Exhibit 104&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant)

---

| | |
|:---|:---|
| By: | /s/ Stephanie M. Kelly |
|  | Stephanie M. Kelly |
|  | Chief Securities and Governance Counsel, Corporate Secretary |

---

Date: April 2, 2026

## Exhibit 99.1

**Exhibit 99.1**

**<u>Non-GAAP Financial Measures Included in the Financial Tables</u>**

The unaudited financial information included herein contains certain financial measures that differ from those presented in accordance with generally accepted accounting principles in the United States ("non-GAAP measures"). These non-GAAP measures include adjustments to certain line items in the attached recast historical financial information to adjust for purchase accounting adjustments; integration, restructuring, and transaction costs; financing impacts; separation-related items; certain regulatory costs; certain product, litigation, and other items; and the income tax benefit of these items, which affect the comparability of period-over-period calculations of diluted earnings per share. In particular, adjustments for fiscal year 2024 exclude the impact of European regulatory initiative-related costs, which represent costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation (collectively, the "New EU Medical Devices Regulations"), which represent a significant, unusual change to the existing regulatory framework. We consider the excluded European regulatory initiative-related costs to be duplicative of previously incurred costs and/or one-off costs related to establishing initial compliance with such regulatory regimes, and in each case are limited to a specific period of time. These expenses relate to establishing initial compliance with the New EU Medical Devices Regulations and include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. These costs were primarily recorded in *Cost of products sold* and *Research and development expense*. These adjustments are consistent with the adjustments made by BD when it reported its operating results for the periods presented.

BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the Company's performance, especially when comparing such results to prior periods or forecasts. We believe presenting such measures provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Earnings per share amounts presented are calculated from the underlying amounts.

------

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Year 2026** | **Fiscal Year 2025** | **Fiscal Year 2025** | **Fiscal Year 2025** | **Fiscal Year 2025** | **Fiscal Year 2025** | **Fiscal Year 2024** |
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2024** | **Three Months Ended March 31, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2024** |
| REVENUES | $4486 | $4333 | $4480 | $4726 | $5005 | $18544 | $16820 |
| Cost of products sold | 2434 | 2536 | 2619 | 2490 | 2639 | 10285 | 9372 |
| Selling and administrative expense | 1229 | 1155 | 1117 | 1163 | 1208 | 4643 | 4250 |
| Research and development expense | 235 | 243 | 232 | 230 | 264 | 970 | 896 |
| Integration, restructuring and transaction expense | 108 | 89 | 93 | 96 | 125 | 403 | 365 |
| Other operating expense, net | 13 | 28 | 35 | 7 | 232 | 302 | 223 |
| TOTAL OPERATING COSTS AND EXPENSES | 4018 | 4051 | 4097 | 3986 | 4469 | 16603 | 15106 |
| OPERATING INCOME | 468 | 282 | 383 | 740 | 536 | 1941 | 1713 |
| Interest expense | (153) | (155) | (150) | (152) | (155) | (613) | (528) |
| Interest income | 4 | 22 | 5 | 4 | 4 | 35 | 162 |
| Other expense, net | (7) | (13) | (36) | (23) | (33) | (105) | (20) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 311 | 136 | 201 | 568 | 352 | 1258 | 1327 |
| Income tax provision (benefit) | 1 | (10) | 43 | 118 | 7 | 158 | 273 |
| NET INCOME FROM CONTINUING OPERATIONS | 311 | 147 | 158 | 450 | 346 | 1100 | 1054 |
| Income from discontinued operations, net of tax | 71 | 157 | 150 | 123 | 148 | 577 | 651 |
| NET INCOME | $382 | $303 | $308 | $574 | $493 | $1678 | $1705 |
| BASIC EARNINGS PER SHARE |  |  |  |  |  |  |  |
| Income from Continuing Operations | $1.09 | $0.51 | $0.55 | $1.57 | $1.21 | $3.83 | $3.64 |
| Income from Discontinued Operations | 0.25 | 0.54 | 0.52 | 0.43 | 0.51 | 2.01 | 2.25 |
| Basic Earnings per Share | $1.34 | $1.05 | $1.07 | $2.00 | $1.72 | $5.83 | $5.88 |
| DILUTED EARNINGS PER SHARE |  |  |  |  |  |  |  |
| Income from Continuing Operations | $1.09 | $0.50 | $0.55 | $1.57 | $1.20 | $3.81 | $3.62 |
| Income from Discontinued Operations | 0.25 | 0.54 | 0.52 | 0.43 | 0.51 | 2.00 | 2.24 |
| Diluted Earnings per Share | $1.34 | $1.04 | $1.07 | $2.00 | $1.72 | $5.82 | $5.86 |
| AVERAGE SHARES OUTSTANDING (in thousands) |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Basic | 285582 | 289505 | 287293 | 287170 | 286612 | 287648 | 289763 |
| &nbsp;&nbsp;&nbsp;&nbsp; Diluted | 285845 | 290389 | 287737 | 287223 | 287118 | 288509 | 291009 |

---

------

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** |
| | **Reported (GAAP)** | **Purchase accounting adjustments<br>(A)** | **Integration costs<br>(B)** | **Restructuring costs<br>(B)** | **Separation-related items<br>(D)** | **Product, litigation, and other items<br>(E)** | **TSA/LSA total** | **Income tax benefit of special items** | **Adjusted (Non-GAAP)** |
| | **Reported (GAAP)** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **Adjusted (Non-GAAP)** |
| REVENUES | $4486 | $— | $— | $— | $— | $— | $— | $— | $4486 |
| Gross margin | 2052 | 384 |  |  |  |  |  |  | 2436 |
| Selling and administrative expense | 1229 |  |  |  |  | (6) |  |  | 1223 |
| Research and development expense | 235 |  |  |  |  | (3) |  |  | 232 |
| OPERATING INCOME | 468 | 384 | 36 | 71 | 1 | 19 | (2) |  | 978 |
| Net interest expense | (149) | (1) |  |  |  |  |  |  | (150) |
| Other (expense) income, net | (7) |  |  |  |  | (11) | 2 |  | (17) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 311 | 383 | 36 | 71 | 1 | 8 |  |  | 811 |
| Income tax provision | 1 |  |  |  |  |  |  | 95 | 95 |
| NET INCOME FROM CONTINUING OPERATIONS | $311 | $383 | $36 | $71 | $1 | $8 | $— | $(95) | $716 |
| DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS | $1.09 | $1.34 | $0.13 | $0.25 | $0.01 | $0.03 | $— | $(0.33) | $2.50 |

---

------

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Reported (GAAP)** | **Purchase accounting adjustments<br>(A)** | **Integration costs<br>(B)** | **Restructuring costs<br>(B)** | **Transaction costs<br>(C)** | **Product, litigation, and other items<br>(E)** | **TSA/LSA total** | **Income tax benefit of special items** | **Adjusted<br>(Non-GAAP)** |
| | **Reported (GAAP)** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **Adjusted<br>(Non-GAAP)** |
| REVENUES | $4333 | $— | $— | $— | $— | $— | $— | $— | $4333 |
| Gross margin | 1797 | 562 |  |  |  | 28 |  |  | 2387 |
| Selling and administrative expense | 1155 | (1) |  |  |  | (9) |  |  | 1145 |
| Research and development expense | 243 |  |  |  |  | (8) |  |  | 235 |
| OPERATING INCOME | 282 | 563 | 24 | 62 | 3 | 75 | (3) |  | 1005 |
| Net interest expense | (133) | (1) |  |  |  |  |  |  | (134) |
| Other (expense) income, net | (13) |  |  |  |  | (3) | 3 |  | (14) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 136 | 562 | 24 | 62 | 3 | 72 |  |  | 858 |
| Income tax (benefit) provision | (10) |  |  |  |  |  |  | 61 | 51 |
| NET INCOME FROM CONTINUING OPERATIONS | $147 | $562 | $24 | $62 | $3 | $72 | $— | $(61) | $808 |
| DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS | $0.50 | $1.93 | $0.08 | $0.21 | $0.01 | $0.25 | $— | $(0.21) | $2.78 |

---

------

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **Reported (GAAP)** | **Purchase accounting adjustments<br>(A)** | **Integration costs<br>(B)** | **Restructuring costs<br>(B)** | **Product, litigation, and other items<br>(E)** | **TSA/LSA total** | **Income tax benefit of special items** | **Adjusted <br>(Non-GAAP)** |
| | **Reported (GAAP)** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **Adjusted <br>(Non-GAAP)** |
| REVENUES | $4480 | $— | $— | $— | $— | $— | $— | $4480 |
| Gross margin | 1861 | 544 |  |  | 87 |  |  | 2492 |
| Selling and administrative expense | 1117 |  |  |  | 9 |  |  | 1126 |
| Research and development expense | 232 |  |  |  | (2) |  |  | 230 |
| OPERATING INCOME | 383 | 544 | 26 | 66 | 115 | (3) |  | 1133 |
| Net interest expense | (146) | (1) |  |  |  |  |  | (147) |
| Other (expense) income, net | (36) |  |  |  | 24 | 3 |  | (9) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 201 | 543 | 26 | 66 | 139 |  |  | 977 |
| Income tax provision | 43 |  |  |  |  |  | 129 | 173 |
| NET INCOME FROM CONTINUING OPERATIONS | $158 | $543 | $26 | $66 | $139 | $— | $(129) | $804 |
| DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS | $0.55 | $1.89 | $0.09 | $0.23 | $0.48 | $— | $(0.45) | $2.79 |

---

------

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** |
| | **Reported (GAAP)** | **Purchase accounting adjustments<br>(A)** | **Integration costs<br>(B)** | **Restructuring costs<br>(B)** | **Transaction costs<br>(C)** | **Product, litigation, and other items<br>(E)** | **TSA/LSA total** | **Income tax benefit of special items** | **Adjusted <br>(Non-GAAP)** |
| | **Reported (GAAP)** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **Adjusted <br>(Non-GAAP)** |
| REVENUES | $4726 | $— | $— | $— | $— | $— | $— | $— | $4726 |
| Gross margin | 2235 | 377 |  |  |  | (1) |  |  | 2612 |
| Selling and administrative expense | 1163 |  |  |  |  | (20) |  |  | 1143 |
| Research and development expense | 230 |  |  |  |  | (2) |  |  | 228 |
| OPERATING INCOME | 740 | 378 | 37 | 57 | 1 | 26 | (3) |  | 1237 |
| Net interest expense | (148) | (1) |  |  |  |  |  |  | (149) |
| Other (expense) income, net | (23) |  |  |  |  | 18 | 3 |  | (2) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 568 | 376 | 37 | 57 | 1 | 44 |  |  | 1085 |
| Income tax provision | 118 |  |  |  |  |  |  | 83 | 201 |
| NET INCOME FROM CONTINUING OPERATIONS | $450 | $376 | $37 | $57 | $1 | $44 | $— | $(83) | $884 |
| DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS | $1.57 | $1.31 | $0.13 | $0.20 | $0.01 | $0.15 | $— | $(0.29) | $3.08 |

---

------

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** |
| | **Reported (GAAP)** | **Purchase accounting adjustments<br>(A)** | **Integration costs<br>(B)** | **Restructuring costs<br>(B)** | **Separation-related items<br>(D)** | **Product, litigation, and other items<br>(E)** | **TSA/LSA total** | **Income tax benefit of special items** | **Adjusted <br>(Non-GAAP)** |
| | **Reported (GAAP)** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **Adjusted <br>(Non-GAAP)** |
| REVENUES | $5005 | $— | $— | $— | $— | $— | $— | $— | $5005 |
| Gross margin | 2366 | 384 |  |  |  | 1 |  |  | 2751 |
| Selling and administrative expense | 1208 |  |  |  |  | (13) |  |  | 1195 |
| Research and development expense | 264 |  |  |  |  | (3) |  |  | 261 |
| OPERATING INCOME | 536 | 384 | 41 | 84 | 3 | 247 | (4) |  | 1292 |
| Net interest expense | (151) | (1) |  |  |  |  |  |  | (152) |
| Other (expense) income, net | (33) |  |  |  |  | 3 | 4 |  | (26) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 352 | 383 | 41 | 84 | 3 | 250 |  |  | 1114 |
| Income tax provision | 7 |  |  |  |  |  |  | 170 | 177 |
| NET INCOME FROM CONTINUING OPERATIONS | $346 | $383 | $41 | $84 | $3 | $250 | $— | $(170) | $937 |
| DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS | $1.20 | $1.33 | $0.14 | $0.29 | $0.01 | $0.87 | $— | $(0.59) | $3.26 |

---

------

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** | **Twelve Months Ended September 30, 2025** |
| | **Reported (GAAP)** | **Purchase accounting adjustments<br>(A)** | **Integration costs<br>(B)** | **Restructuring costs<br>(B)** | **Transaction costs<br>(C)** | **Separation-related items<br>(D)** | **Product, litigation, and other items<br>(E)** | **TSA/LSA total** | **Income tax benefit of special items** | **Adjusted <br>(Non-GAAP)** |
| | **Reported (GAAP)** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **Adjusted <br>(Non-GAAP)** |
| REVENUES | $18544 | $— | $— | $— | $— | $— | $— | $— | $— | $18544 |
| Gross margin | 8258 | 1867 |  |  |  |  | 115 |  |  | 10241 |
| Selling and administrative expense | 4643 | (2) |  |  |  |  | (33) |  |  | 4609 |
| Research and development expense | 970 |  |  |  |  |  | (15) |  |  | 955 |
| OPERATING INCOME | 1941 | 1869 | 127 | 270 | 6 | 3 | 463 | (12) |  | 4666 |
| Net interest expense | (577) | (4) |  |  |  |  |  |  |  | (582) |
| Other (expense) income, net | (105) |  |  |  |  |  | 43 | 12 |  | (50) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 1258 | 1865 | 127 | 270 | 6 | 3 | 506 |  |  | 4034 |
| Income tax provision | 158 |  |  |  |  |  |  |  | 443 | 601 |
| NET INCOME FROM CONTINUING OPERATIONS | $1100 | $1865 | $127 | $270 | $6 | $3 | $506 | $— | $(443) | $3433 |
| DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS | $3.81 | $6.46 | $0.44 | $0.93 | $0.02 | $0.01 | $1.75 | $— | $(1.54) | $11.90 |

---

------

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** | **Twelve Months Ended September 30, 2024** |
| | **Reported (GAAP)** | **Purchase accounting adjustments<br>(A)** | **Integration costs<br>(B)** | **Restructuring costs<br>(B)** | **Transaction costs<br>(C)** | **Financing impacts<br>(C)** | **Separation-related items<br>(D)** | **Product, litigation, and other items<br>(E)** | **European regulatory initiative-related costs<br>(F)** | **TSA/LSA total** | **Income tax benefit of special items** | **Adjusted (Non-GAAP)** |
| | **Reported (GAAP)** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **See Footnotes on Page 10** | **Adjusted (Non-GAAP)** |
| REVENUES | $16820 | $— | $— | $— | $— | $— | $— | $67 | $— | $— | $— | $16887 |
| Gross margin | 7448 | 1482 |  |  |  |  |  | 115 | 43 |  |  | 9088 |
| Selling and administrative expense | 4250 | 1 |  |  |  |  |  | (56) | (1) |  |  | 4194 |
| Research and development expense | 896 |  |  |  |  |  |  | (4) | (54) |  |  | 838 |
| OPERATING INCOME | 1713 | 1481 | 23 | 294 | 48 |  | 13 | 393 | 98 | 27 |  | 4091 |
| Net interest expense | (366) | (5) |  |  |  | (8) |  |  |  |  |  | (379) |
| Other expense, net | (20) |  |  |  |  |  |  | (51) |  | (27) |  | (98) |
| INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 1327 | 1477 | 23 | 294 | 48 | (8) | 13 | 342 | 98 |  |  | 3614 |
| Income tax provision | 273 |  |  |  |  |  |  |  |  |  | 267 | 540 |
| NET INCOME FROM CONTINUING OPERATIONS | $1054 | $1477 | $23 | $294 | $48 | $(8) | $13 | $342 | $98 | $— | $(267) | $3074 |
| DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS | $3.62 | $5.07 | $0.08 | $1.01 | $0.17 | $(0.03) | $0.05 | $1.17 | $0.34 | $— | $(0.92) | $10.56 |

---

------

The reconciliations of reported results to adjusted results on the previous pages reflect the following adjustments that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)Includes amortization and other adjustments related to the purchase accounting for acquisitions. BD's amortization expense is primarily recorded in *Cost of products sold*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)Represents costs associated with integration and restructuring activities. These costs are recorded to *Integration, restructuring and transaction expense*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)Represents transaction costs and financing impacts incurred in connection with the Advanced Patient Monitoring acquisition. The transaction costs are recorded to *Integration, restructuring and transaction expense*, and the financing impacts are recorded to *Interest expense* and *Interest income.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)Amounts in fiscal years 2026 and 2025 represent costs incurred in connection with the separation of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation. The amount in fiscal year 2024 represents costs incurred in connection with the separation of BD's former Diabetes Care business. These costs are recorded to *Other operating expense, net*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amounts presented include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Charges of $297 million in fiscal year 2025 related to product liability and certain other legal matters, recorded to *Other operating expense, net*. The amount in fiscal year 2024 reflects charges related to product liability and certain other legal matters, recorded to *Other operating expense, net*, including a $175 million charge to accrue an estimated liability for the SEC investigation with respect to, among other things, certain reporting issues involving BD Alaris<sup>TM</sup> infusion pumps included in SEC disclosures prior to 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Charges to adjust the estimate of future product remediation costs, recorded to *Cost of products sold,* of $98 million and $38 million in fiscal years 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Charges related to pension settlement costs, recorded to *Other expense*, *net*, of $38 million in fiscal year 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The recognition of $67 million in accruals in fiscal year 2024 as an impact to *Revenues* relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are primarily recorded in *Cost of products sold* and *Research and development expense*, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.